There is strong Level 1a evidence (from 2 RCTs; Banovac et al. 2001; Banovac et al. 2004) that non-steroidal anti-inflammatory medications can reduce the incidence of heterotopic ossification when administered early after a spinal cord injury.
There is Level 5 evidence (from 1 observational study; Buschbacher et al. 1992) that Warfarin inhibits the development of heterotopic ossification post spinal cord injury.
There is Level 2 evidence (from 2 prospective controlled trials; Banovac et al. 1993; Banovac et al. 1997) that Etidronate can stop the progression of heterotopic ossification once the diagnosis is made; it is most effective if treatment is provided when the bone scan is positive but the radiographs are negative.
There is Level 2 evidence (from 1 prospective controlled trial; Banovac et al. 1997) that Etidronate is not effective once radiographs are positive for HO.
There is Level 4 evidence (from 1 case series; Schuetz et al. 2005) that pamidronate effectively halts secondary HO progression after surgical resection of HO.
There is Level 1b evidence (from 1 RCT; Durovic et al. 2009) that Pulse Low Intensity Electromagnetic Field therapy is an effective prophylaxis of HO post SCI
There is limited Level 4 evidence (from 2 case series studies; Sautter-Bihl et al. 2000; Sautter-Bihl et al. 2001) that radiotherapy reduces the progression of heterotopic ossification.
There is level 4 evidence (from 3 case series studies; Genet et al. 2011; Garland & Orwin 1989; Meiners et al. 1997) that resection of HO about the hip post SCI can dramatically improve restricted hip range of motion.
There is Level 4 evidence (from 1 case series study; Schuetz et al. 2005) that surgical resection combined with pamidronate treatment effectively halts secondary HO progression.